Morphosis Capital
Morphosis Capital is a founder-centric Romanian private equity firm operating two institutional funds (€50M Fund I, €130M Fund II) that invest €10-15 million growth tickets into SMEs with €1-5 million EBITDA across healthcare, technology, niche manufacturing, consumer/retail, and B2B services in Romania and Central/Eastern Europe.
- Company typePrivate
- Founded2018
- HeadquartersBucharest, Romania
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Morphosis Capital does
Morphosis Capital is a founder-centric regional private equity firm established in December 2018 by four Romanian entrepreneurs — Simona Gemeneanu, Andrei Gemeneanu (Managing Partner), Dragoș Petre (Partner & CFO), and Gabriela Dumitru. The firm invests growth capital of €10-15 million per transaction into SMEs in Romania and broader Central and Eastern Europe (Bulgaria, Croatia, Czechia, Poland, Slovakia), targeting companies with €1-5 million EBITDA across healthcare, technology, niche manufacturing, consumer/retail, and B2B services. It operates two institutional-grade funds: Fund I (€50M committed, December 2018) and Fund II (€130M committed, closed September 2025), with combined committed capital exceeding €180M and anchor backing from EIF, EBRD, and IFC.
The firm offers both minority and majority equity structures, with operating support in marketing, sales, M&A, HR, and management rather than purely financial capital. The current active portfolio comprises eight companies — Echo Elderly Care (senior care platform launched December 2025), EnduroSat (Bulgarian space infrastructure, invested February 2025), Romania Education Alliance (K12 platform, January 2024), Medima (medical imaging), EMI Group (industrial access systems), Cronos Med (aesthetic medicine), and Stay Fit Gym (fitness) — supported by a team of approximately 11 investment professionals. Three full exits have been completed: Dr. Leahu Dental Clinics to Regina Maria (June 2023), DocProcess to AGENA3000 (September 2025), and La Cocos to Schwarz Group (March 2026), with Fund I having achieved a 30%+ IRR.
Morphosis generates revenue through traditional PE fund-management economics: management fees charged on committed capital and carried interest on exits above the hurdle rate. The firm's legal entities are Morphosis Capital Partners B.V. (registered in The Hague, Netherlands) and Morphosis Capital Fund I Coöperatief U.A. (Amsterdam, Netherlands), while investment activity is concentrated in Romania. Deal flow is sourced primarily through direct founder networks, referrals, and institutional co-investor relationships rather than open deal auctions, and the firm has executed 13 bolt-on acquisitions across its portfolio between 2021 and 2023 to support buy-and-build consolidation strategies in fragmented CEE markets.
Morphosis Capital firmographics
Firmographics- Name
- Morphosis Capital
- Legal name
- Morphosis Capital SRL
- Website
- https://morphosiscapital.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Morphosis Capital is a founder-centric Romanian private equity firm operating two institutional funds (€50M Fund I, €130M Fund II) that invest €10-15 million growth tickets into SMEs with €1-5 million EBITDA across healthcare, technology, niche manufacturing, consumer/retail, and B2B services in Romania and Central/Eastern Europe.
- Ownership category
- akta.pro rank
Where Morphosis Capital is headquartered
LocationHeadquarters
- HQ city
- Bucharest
- HQ country
- Romania
- HQ region
- Europe
Offices2 records
Markets served
Morphosis Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others, Infrastructure
Revenue model
- Private Equity Fund Management: Morphosis Capital generates returns through management fees (typically charged on committed capital) and carried interest (share of profits above hurdle rate from successful portfolio company exits). The fund's revenue is tied to investment performance and successful exits from portfolio companies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Morphosis Capital product offering
Product offeringCore offering
Morphosis Capital manages two regional private equity funds (Fund I €50M, Fund II €130M) that deploy €5–15 million tickets of growth capital into SMEs with EBITDA of €1–5 million in Romania and Central/Eastern Europe. The firm acquires both minority and majority equity stakes in healthcare, technology, niche manufacturing, consumer/retail and B2B services companies and provides hands-on operational support in sales, marketing, M&A, HR and international expansion.
Product overview
Morphosis Capital is a founder-centric regional private equity firm operating two investment funds: Morphosis Capital Fund I (€50M, established 2018) and Morphosis Capital Fund II (€130M, launched 2024). The funds invest in high-growth SMEs across Romania and Central Europe, focusing on healthcare, technology, niche manufacturing, consumer products/retail, and B2B services. Fund I targets companies with EBITDA over €0.5M, deploying €5-15M tickets, while Fund II targets EBITDA of €1-5M with €10-15M investments. The current portfolio includes 8 companies: Echo Elderly Care (elderly care platform), EnduroSat (satellite services), Romania Education Alliance (education), Medima (medical imaging), EMI (industrial access systems), Cronos Med (aesthetic medicine), and Stay Fit Gym (fitness). Previous investments exited include DocProcess, Dr. Leahu Dental Clinics, and La Cocos.
Differentiator
Problem solved
Functional benefit
Brands
- Echo Elderly Care: National platform for high-quality elderly care and active aging services, created through strategic acquisitions and greenfield investments.
- Romania Education Alliance
Products and services
- Morphosis Capital Fund I A €50 million regional private equity fund that invests equity capital (€5–15 million per company) in high-growth Romanian SMEs with EBITDA between €0.5M and €5M, targeting healthcare, technology, niche manufacturing and B2B services. Designed for entrepreneurial founders seeking growth capital plus operational support.
- Morphosis Capital Fund II A €130 million growth capital private equity fund investing in Romanian and Central/Eastern European SMEs with EBITDA of €1–5 million, deploying €10–15 million equity tickets across healthcare, B2B services, consumer products/retail and niche manufacturing sectors.
Quantifiable outcome
- 30%+ IRR achieved by Fund I
- +4 more outcomes
Companies that use Morphosis Capital
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles2 records
Morphosis Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Morphosis Capital partnerships and signals
Strategic signalScale indicators23 records
Recent moves11 records
Expansion highlights6 records
Morphosis Capital competitors and assessment
Company assessmentBroad incumbents
- Mid Europa Partners: Largest dedicated CEE private equity firm (multi-billion AUM), investing in growth and buyouts across Central Europe. Overlap with Morphosis on CEE focus and growth-stage tickets makes it a benchmark incumbent peer.
Direct peers
- Abris Capital Partners: CEE-focused private equity firm executing mid-market buyouts and growth investments in Romania, Poland, and broader CEE. Closest pure-play competitor to Morphosis given similar geography, ticket size, and sector breadth.
- 3TS Capital Partners: Central European growth equity firm focused on SMEs with €5-25M tickets across tech-enabled services, healthcare, and B2B. Directly comparable to Morphosis in CEE SME growth-equity positioning.
- Enterprise Investors: Polish/CEE private equity manager with a 30+ year track record investing in mid-market growth and buyouts in Romania, Poland, and the Baltic region. Direct overlap in geography, ticket size, and founder-led SME thesis.
- BlackPeak Capital: Southeast European growth capital firm investing in SMEs in Romania, Bulgaria, and the Balkans. Highly comparable business model, ticket size range, and sector focus to Morphosis.
- Innova Capital: Polish private equity firm deploying mid-market tickets into CEE SMEs. Morphosis's documented co-investor in EMI Group, indicating active operational overlap and shared deal-sourcing network.
- CEECAT Capital: Growth equity firm focused exclusively on SMEs in Central and Eastern Europe. Co-invested with Morphosis in La Cocos, and operates an adjacent CEE SME growth mandate.
- Integral Venture Partners: Growth equity firm investing €5-25M tickets into SMEs across emerging Europe, with an evolving Europe mandate. Morphosis's co-investor in Medima Health and operates in a near-identical strategy.
Regional players
- Argus Capital Group: Romanian-domiciled private equity firm investing in Romanian SMEs. Comparable founder-centric SME thesis but with a more Romania-only focus than Morphosis's emerging CEE scope.
- Catalyst Romania: Romanian private equity fund-of-funds and co-investment platform with dedicated activity in Romanian SMEs. Adjacent ecosystem participant sharing deal-flow networks with Morphosis in Romania.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Morphosis Capital social profiles
Digital presenceMorphosis Capital compliance and trust
Trust signalCompliance1 record
Morphosis Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Morphosis Capital leadership team
Management profileNumber of profiles
Profiles12 records
Morphosis Capital subsidiaries and ownership
Company hierarchySubsidiaries10 records
Morphosis Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Morphosis Capital M&A and investment
M&A and investmentM&A
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Morphosis Capital
What does Morphosis Capital do?
Morphosis Capital manages two regional private equity funds (Fund I €50M, Fund II €130M) that deploy €5–15 million tickets of growth capital into SMEs with EBITDA of €1–5 million in Romania and Central/Eastern Europe. The firm acquires both minority and majority equity stakes in healthcare, technology, niche manufacturing, consumer/retail and B2B services companies and provides hands-on operational support in sales, marketing, M&A, HR and international expansion.
Is Morphosis Capital a public or private company?
Morphosis Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Morphosis Capital founded?
Morphosis Capital was founded in 2018. It employs 1,001 to 5,000 people.
Where is Morphosis Capital based?
Morphosis Capital is headquartered in Bucharest, Romania, in the Europe region.
How does Morphosis Capital make money?
One revenue line is on record: private Equity Fund Management.
Who are Morphosis Capital's main competitors?
Mid Europa Partners is listed as a broad incumbent. Direct peers are Abris Capital Partners, 3TS Capital Partners, Enterprise Investors, BlackPeak Capital, Innova Capital, CEECAT Capital and Integral Venture Partners. Regional players are Argus Capital Group and Catalyst Romania.
Does Morphosis Capital have an API?
No public API is recorded for Morphosis Capital.